InsiderTrades.com logo
Lauren Merendino net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Lauren Merendino Biography and Net Worth

Insider of Day One Biopharmaceuticals

Lauren Merendino is a seasoned commercial leader with over 25 years of pharmaceutical & biotech leadership with expertise in building and leading commercial teams and a record of successful product launches. In her current role, she has led the launch of our inaugural product, OJEMDA, delivering outstanding performance.

Previously, as Chief Commercial Officer at Myovant Sciences, Lauren led the successful launches of two products across 3 indications in the span of 2 years. Lauren spent the majority of her career at Genentech/Roche, where she held various commercial leadership roles on multiple launches. In her final role at Genentech, she was the Head of the Neurological Rare Diseases therapeutic area where she led a cross-functional team to launch a novel therapy in SMA, which quickly grew to become the market leader.

Lauren’s career is built on a deep foundation of Marketing, Sales and leadership experience, with a depth of experience from over 15 years in oncology. Lauren also served as a Director on the Board of ESSA Pharmaceuticals from June 2023 to March 2025. Lauren has a Bachelors of Science in Microbiology from Penn State University and completed her MBA at New York University.

What is Lauren Merendino's net worth?

The estimated net worth of Lauren Merendino is at least $423.75 thousand as of November 17th, 2025. Merendino owns 50,809 shares of Day One Biopharmaceuticals stock worth more than $423,747 as of December 5th. This net worth approximation does not reflect any other investments that Merendino may own. Learn More about Lauren Merendino's net worth.

How old is Lauren Merendino?

Merendino is currently 48 years old. There are 4 older executives and no younger executives at Day One Biopharmaceuticals. The oldest executive at Day One Biopharmaceuticals is Mr. Adam Dubow, General Counsel, who is 57 years old. Learn More on Lauren Merendino's age.

How do I contact Lauren Merendino?

The corporate mailing address for Merendino and other Day One Biopharmaceuticals executives is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. Day One Biopharmaceuticals can also be reached via phone at 650-484-0899 and via email at [email protected]. Learn More on Lauren Merendino's contact information.

Has Lauren Merendino been buying or selling shares of Day One Biopharmaceuticals?

Over the course of the past ninety days, Lauren Merendino has sold $33,198.66 in shares of Day One Biopharmaceuticals stock. Most recently, Lauren Merendino sold 3,726 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $8.91, for a transaction totalling $33,198.66. Following the completion of the sale, the insider now directly owns 50,809 shares of the company's stock, valued at $452,708.19. Learn More on Lauren Merendino's trading history.

Who are Day One Biopharmaceuticals' active insiders?

Day One Biopharmaceuticals' insider roster includes Jeremy Bender (CEO), Samuel Blackman (Insider), Adam Dubow (General Counsel), Papanek Grant (Director), Lauren Merendino (Insider), Saira Ramasastry (Director), and Charles York, II (Chief Operating and Financial Officer). Learn More on Day One Biopharmaceuticals' active insiders.

Are insiders buying or selling shares of Day One Biopharmaceuticals?

During the last twelve months, insiders at the sold shares 16 times. They sold a total of 134,085 shares worth more than $1,259,570.00. The most recent insider tranaction occured on November, 17th when insider Adam Dubow sold 4,319 shares worth more than $38,482.29. Insiders at Day One Biopharmaceuticals own 6.2% of the company. Learn More about insider trades at Day One Biopharmaceuticals.

Information on this page was last updated on 11/17/2025.

Lauren Merendino Insider Trading History at Day One Biopharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2025Sell3,726$8.91$33,198.6650,809View SEC Filing Icon  
8/18/2025Sell3,766$6.77$25,495.8241,931View SEC Filing Icon  
5/16/2025Sell3,927$6.26$24,583.0235,161View SEC Filing Icon  
See Full Table

Lauren Merendino Buying and Selling Activity at Day One Biopharmaceuticals

This chart shows Lauren Merendino's buying and selling at Day One Biopharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Day One Biopharmaceuticals Company Overview

Day One Biopharmaceuticals logo
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $8.34
Low: $8.21
High: $8.60

50 Day Range

MA: $8.08
Low: $6.77
High: $10.36

2 Week Range

Now: $8.34
Low: $5.64
High: $13.92

Volume

2,072,215 shs

Average Volume

2,762,046 shs

Market Capitalization

$856.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A